{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-23-008942","form_type":"8-K","ticker":null,"cik":"0001617765","company_name":"EVOME MEDICAL TECHNOLOGIES INC.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.683586+00:00","generated_at":"2026-06-17T04:36:44.412198+00:00","sec_items":["2.01","2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Salona Global closes Biodex acquisition for $8M; reports 167% revenue growth to $33.6M","bullets":["Acquired Biodex for $1M cash + $7M in installments; adds projected $26M annual revenue at ~30% gross margin.","Transition period revenue $33.6M (167% YoY growth); gross margin $10.6M (31.4% of revenue).","Adjusted EBITDA $435,948 (17% YoY growth); preliminary Feb 2023 revenue ~$6.7M, EBITDA ~$200K.","Combined annualized revenue estimated at ~$65M with ~34% gross margin; order backlog ~$20M.","Appointed Joe Martinez as SVP, Legal & Compliance, General Counsel effective March 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-23-008942","json":"https://secwatch.observer/filing/0001062993-23-008942.json","markdown":"https://secwatch.observer/filing/0001062993-23-008942.md","text":"https://secwatch.observer/filing/0001062993-23-008942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:36:44.412198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3afbe7dad2d1d3d3bbbf9896dbe6b7b6b61d1d50","claim":"EVOME MEDICAL TECHNOLOGIES INC. reported next 12 months results: revenue $65 million. Guidance initiated.","evidence_excerpt":"With the addition of our new Biodex Physical Medicine business, the Company estimates that it will generate Annualized Revenue (defined below) of approximately $65 million, with a gross margins of approximately 34%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"next 12 months"},{"label":"Revenue","value":"$65 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"bb8f8557cedcace599479fdb5fc382df39057d5a","claim":"EVOME MEDICAL TECHNOLOGIES INC. reported ten months ended December 31, 2022 results: revenue $33.6 million.","evidence_excerpt":"The Company also posted its audited year-end financial statements for the ten month transition period ended December 31, 2022, with a total of $33.6 million in revenue with 31.4% gross margins for the period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"ten months ended December 31, 2022"},{"label":"Revenue","value":"$33.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ce42149fdf02cd5f3e1f5e5a73b607dae282510f","claim":"EVOME MEDICAL TECHNOLOGIES INC. reported two months ended February 28, 2023 results: revenue $6.7 million.","evidence_excerpt":"Through February 2023, the Company estimates on a preliminary basis that it is has generated revenues of approximately $6.7 million with gross profit exceeding 35% and EBITDA of approximately $200,000.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"two months ended February 28, 2023"},{"label":"Revenue","value":"$6.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"603ca5f6ba65d6eed6a036a086e8f315ddc3a081","claim":"EVOME MEDICAL TECHNOLOGIES INC. completed an acquisition involving Mirion Technologies (US), Inc. for $1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million (closed 2023-04-03).","evidence_excerpt":"corporation ( \"Biodex\" ), which consists principally of the Biodex Physical Medicine (Rehabilitation) business (the \"Acquisition\" ). The consideration for the Acquisition was $1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million, plus or minus a post-closing adjustment, as follows: $2 million on July 1, 2023, $3","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Mirion Technologies (US), Inc."},{"label":"Consideration","value":"$1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million"},{"label":"Closing","value":"2023-04-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}